Steroid formulation
Patent 4448774 Issued on May 15, 1984. Estimated Expiration Date: 
December 22, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
December 22, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesAnti-inflammatory steroid Use of derivatives of 6-methylprednisolone as an antiemetic Steroid formulation containing dipotassium EDTA Patent #: 4344940 InventorsAssigneeApplicationNo. 06/452294 filed on 12/22/1982US Classes:514/179Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)ExaminersPrimary: Roberts, Elbert L.Attorney, Agent or FirmInternational ClassesA61K 9/00 (20060101)A61K 31/57 (20060101) AbstractThere is described an aqueous pharmaceutical solution comprising a steroid selected from prednisolone, prednisolone sodium phosphate, prednisone and methyl prednisolone, the steroid being present at a concentration of at least 0.3 mg/ml., the pH of the formulation between 5 and 8 and the formulation containing a pharmaceutically acceptable preservative, a pharmaceutically acceptable chelating agent, and being substantially free of ethanol.There is also described a method of treatment of a variety of conditions, particularly in children, using the solution. | |
